Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DBH | P09172 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SELL | P14151 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891340 | 0.80 | ALDH1A1 (0.41) | KDM4EGAAPDK2PIK3CANOTUM | |
| SCHEMBL12231333 | 0.79 | HSP90AB1 (0.47) | KDM4ERECQLPDK2HSP90AA1HSP90AB1 | |
| SCHEMBL32679234 | 0.79 | FFAR1 (0.44) | GRM2FFAR1PIK3CA | |
| SCHEMBL1831012 | 0.79 | FFAR1 (0.44) | GRM2FFAR1PIK3CA | |
| SCHEMBL32679233 | 0.79 | FFAR1 (0.44) | GRM2FFAR1PIK3CA | |
| SCHEMBL18677489 | 0.78 | SELL (0.57) | KDM4EGAARECQLPIK3CASELL | |
| SCHEMBL12231292 | 0.77 | ALDH1A1 (0.46) | RECQLHSP90AA1HSP90AB1PIK3CA | |
| SCHEMBL16097744 | 0.76 | CFTR (0.47) | KDM4EGAAPDK2 | |
| SCHEMBL1827944 | 0.73 | GAA (0.44) | KDM4EDBHGAARECQLFFAR1 | |
| SCHEMBL15631126 | 0.73 | KDM4E (0.44) | KDM4EDBHGAARECQLFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2318375-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2010009062-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | CYP3A4, CYP2C9, AADAC | GRM2 2836/4885KDM4E 449/4885DBH 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.